NIRS Monitoring for Neonates With Mild Hypoxic-Ischemic Encephalopathy.

Adv Neonatal CareJun 18, 2026 (epub)
Clinical ResearchPediatrics

Pollieanna Sepúlveda, Lizette Lee, Monica Madrid Ornelas et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the use of near-infrared spectroscopy (NIRS) for continuous monitoring of cerebral oxygenation in term neonates with mild hypoxic-ischemic encephalopathy (HIE). The study established clinical practice guidelines recommending NIRS initiation within the first 6 hours of life and continuous monitoring for the first 24 hours. Key thresholds for nursing assessment were identified.

Key findings

  • NIRS should be initiated within the first 6 hours of life for neonates with mild HIE.
  • Continuous cerebral monitoring is recommended for the first 24 hours in this population.
  • Nursing assessment is advised for rScO2 levels <55% and >85%-90%.

Why it matters

Implementing standardized NIRS monitoring guidelines can facilitate early detection of cerebral oxygenation issues, potentially leading to timely neuroprotective interventions in vulnerable neonates with mild HIE.

Source

Published in Adv Neonatal Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.